Home » Stocks » TCRR

TCR2 Therapeutics Inc. (TCRR)

Stock Price: $19.01 USD -0.28 (-1.45%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 724.99M
Revenue (ttm) n/a
Net Income (ttm) -67.12M
Shares Out 27.99M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $19.01
Previous Close $19.29
Change ($) -0.28
Change (%) -1.45%
Day's Open 19.43
Day's Range 18.35 - 19.74
Day's Volume 329,569
52-Week Range 8.71 - 35.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from canc...

17 hours ago - GlobeNewsWire

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca...

2 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from ca...

1 month ago - GlobeNewsWire

-  Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from c...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from ca...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for ...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for ...

3 months ago - GlobeNewsWire

- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21

4 months ago - GlobeNewsWire

- TC-210 induced tumor regression in all of the first eight patients

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering f...

5 months ago - GlobeNewsWire

- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from...

8 months ago - GlobeNewsWire

- TC-210 patient with partial response confirmed by independent central review and tumor regression improved further from 42% to 75%

9 months ago - GlobeNewsWire

Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.

Other stocks mentioned: ALLO, CLLS, GILD, NVS
9 months ago - The Motley Fool

CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies fo...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies fo...

9 months ago - GlobeNewsWire

The company announced positive interim results for one of its experimental treatments.

9 months ago - The Motley Fool

- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients ...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients s...

11 months ago - GlobeNewsWire

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients s...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients...

1 year ago - GlobeNewsWire

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

Other stocks mentioned: AVRO, FATE, KNSA, MRSN, NVCR, ORTX, SYBX
1 year ago - 24/7 Wall Street

About TCRR

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignanci... [Read more...]

Industry
Biotechnology
IPO Date
Feb 14, 2019
CEO
Garry Menzel
Employees
118
Stock Exchange
NASDAQ
Ticker Symbol
TCRR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for TCRR stock is "Strong Buy." The 12-month stock price forecast is 45.67, which is an increase of 140.24% from the latest price.

Price Target
$45.67
(140.24% upside)
Analyst Consensus: Strong Buy